ADMA Biologics delivered record fourth-quarter results, driven by strong demand for ASCENIV and the successful integration of yield-enhanced production. The company achieved significant margin expansion and reiterated its long-term growth targets through 2029.

ADMA Biologics delivered a strong third quarter in 2025, with total revenue increasing by 12% year-over-year to $134.2 million and adjusted EBITDA surging by 29% to $58.7 million. The company achieved a pivotal milestone with FDA lot release of its first yield-enhanced production batches, positioning for significant gross margin expansion. Record demand for ASCENIV and progress in its SG-001 pipeline further underscore a positive growth trajectory.

ADMA Biologics delivered a strong second quarter in 2025, with total revenue reaching $122.0 million, a 14% increase year-over-year. GAAP net income grew by 7% to $34.2 million, while Adjusted EBITDA surged to $50.8 million and Adjusted Net Income to $36.0 million, both showing substantial underlying growth when excluding a prior-year non-recurring item. The company also initiated commercial-scale manufacturing with its yield enhancement process, delivering a 20%+ increase in finished IG output, and completed a $300 million syndicated debt refinancing, significantly lowering borrowing costs.

ADMA Biologics reported a strong start to 2025 with total revenue increasing 40% year-over-year to $114.8 million and GAAP Net Income rising 51% to $26.9 million. Adjusted EBITDA saw an 81% increase to $47.9 million. The company also highlighted the FDA approval of its yield enhancement process and increased its full-year 2025 and 2026 guidance, alongside authorizing a $500 million share repurchase program.

ADMA Biologics achieved $117.5 million in revenue for Q4 2024, reflecting a 59% year-over-year increase. Gross profit more than doubled to $63.3 million, with gross margin improving to 54.0%. The company reported GAAP net income of $111.9 million, significantly reversing a prior-year net loss. Adjusted EBITDA more than doubled to $48.3 million. Strong operational cash flow further strengthened the balance sheet, positioning the company for continued growth.

ADMA Biologics reported a substantial increase in revenue and net income for Q3 2024. Total revenue grew by 78% year-over-year to $119.8 million, while GAAP net income increased by 1,300% to $35.9 million. The company also raised its full-year revenue, net income, and adjusted EBITDA guidance for 2024 and 2025.

ADMA Biologics reported a strong second quarter in 2024, with a 78% increase in total revenue to $107.2 million and a net income of $32.1 million, driven by increased sales of ASCENIV and a favorable product mix. The company's adjusted EBITDA reached $44.5 million, and based on this performance, ADMA has increased its financial guidance for 2024 and 2025.

ADMA Biologics reported a strong first quarter in 2024, marked by a 44% increase in total revenue, achieving $81.9 million. The company's net income reached $17.8 million, and adjusted EBITDA was $26.4 million, reflecting significant year-over-year growth and leading to increased financial guidance for 2024 and 2025.

ADMA Biologics announced strong Q4 2023 results with a 48% increase in total revenues to $73.9 million compared to Q4 2022. The company reported an Adjusted EBITDA of $18.6 million for the quarter, a significant improvement from the Adjusted EBITDA loss of $3.5 million in the same period last year. The company's full year performance marked first-time positive adjusted net income.

ADMA Biologics reported a strong third quarter in 2023, achieving first-time positive GAAP net income and operating cash flow. The company's total revenues increased by 64% year-over-year, driven by increased sales of immunoglobulin products. Adjusted EBITDA also grew significantly, and the company raised its total revenue guidance for 2023, 2024, and 2025.

ADMA Biologics reported a 77% year-over-year increase in total revenues, reaching $60.1 million in Q2 2023. The company's Adjusted EBITDA grew to $6.4 million, representing a 160% increase compared to the first quarter of 2023. ADMA increased its total revenue guidance for FY 2023, 2024 and 2025.

ADMA Biologics reported a 96% year-over-year increase in total revenues, reaching $57 million in Q1 2023. The company achieved first-time Adjusted EBITDA profitability of $2.5 million and narrowed its net loss to $6.8 million. Based on these results, ADMA increased its 2023 total revenue guidance to exceed $220 million.

ADMA Biologics announced strong Q4 2022 results, with a 90% increase in total revenues to $50.0 million compared to Q4 2021. Gross profit increased to $14.2 million, driven by ASCENIV sales. The company anticipates full year 2023 total revenues to exceed $210 million and expects first-time positive EBITDA no later than the second half of 2023.

ADMA Biologics reported a 99% year-over-year increase in total revenues for Q3 2022, reaching $41.1 million. The company also saw a substantial increase in gross profit, driven by a favorable contribution from ASCENIV. They are raising full-year 2022 revenue guidance to $145 million.

ADMA Biologics reported a 90% year-over-year increase in total revenue, reaching $33.9 million for Q2 2022. The company's gross profit increased to $7.8 million, and net losses were narrowed to $13.8 million. ADMA anticipates total 2022 revenues will exceed $130 million.

ADMA Biologics reported an 81% increase in total revenues for Q1 2022, reaching $29.1 million compared to $16.0 million in Q1 2021. The company is increasing full year 2022 total revenue guidance to $130 million or more from $125 million. The company's net loss for the quarter was $25.0 million, which includes $6.7 million in non-recurring charges.

ADMA Biologics reported an 89% increase in total revenues for the fourth quarter of 2021, driven by the commercial ramp-up of its IVIG product portfolio. The company's net loss decreased compared to the same period in the prior year, primarily due to improved gross profit contribution.

ADMA Biologics reported a 101% increase in revenue compared to Q3 2020, reaching $20.7 million. The company achieved a positive gross profit for the first time and narrowed net losses quarter-over-quarter. They also strengthened their cash position through a public equity offering.

ADMA Biologics reported a record $17.8 million in total revenues for Q2 2021, a 129% increase over the same period in 2020. The company also narrowed its net loss compared to the previous year, driven by increased revenues and improved gross margins. ADMA anticipates exiting 2021 approaching an annualized revenue run rate of approximately $100 million or more.

ADMA Biologics reported a strong first quarter in 2021, achieving record quarterly revenues of $16.0 million, a 57% increase over the same period last year. The company also narrowed both gross and net losses compared to the prior quarter and grew its total asset value to $235.7 million.

ADMA Biologics reported a revenue of $14.0 million for the quarter ended December 31, 2020, representing a 16% increase compared to the same period in 2019. The company's net loss for the quarter was $19.4 million, or $(0.20) per share.

ADMA Biologics reported a 42% increase in revenue for the third quarter of 2020, reaching $10.3 million, driven by the commercial ramp-up of BIVIGAM and ASCENIV and a manufacturing supply agreement. However, the company experienced a net loss of $16.9 million, primarily due to increased costs of product revenue, selling, general, and administrative expenses, and research and development expenses.

ADMA Biologics reported a 19% increase in revenue for Q2 2020 compared to Q2 2019, totaling $7.8 million. However, the company experienced a net loss of $20.2 million, primarily due to increased costs of product revenue, research and development expenses, and selling, general, and administrative expenses. The company also faced supply chain disruptions due to the COVID-19 pandemic, which have since been resolved.

ADMA Biologics reported a strong first quarter in 2020, with total revenues increasing by 189% compared to the same period in 2019. The company's net loss increased due to investments in production capacity and commercial infrastructure. ADMA ended the quarter with a strong cash position due to a successful public offering.

ADMA Biologics reported a significant increase in revenue for Q4 2019, driven by the commercial sales of ASCENIV and the relaunch of BIVIGAM. The company also strengthened its balance sheet through a public offering, leading to an improved working capital position.